AAN 2023: ALZ-801 for Alzheimer’s found to improve cognition in trialalzheon2023-05-03T11:24:17-04:00April 28th, 2023|
Oral Anti-Amyloid Shows Disease-Modifying Potential: Phase 2 Dataalzheon2023-05-03T12:05:29-04:00April 28th, 2023|
Why lecanemab’s success spells the revival of small-molecule Alzheimer’s treatmentsalzheon2023-07-31T15:57:28-04:00March 12th, 2023|
Newsweek Investment Report: Interview with Dr. Martin Tolar, President & CEO of Alzheon, Inc.alzheon2023-04-16T12:18:58-04:00February 21st, 2023|
‘It’s night and day’: Biogen’s new Alzheimer’s drug may spur more investment in fighting the diseasealzheon2023-02-18T14:19:25-05:00February 17th, 2023|
I interview Dr. Martin Tolar, Founder, CEO and President of Alzheon on the Phase 3 trial going on right nowalzheon2023-02-16T12:37:20-05:00February 15th, 2023|
Biotech and Business Development Leader Wendy Nelson on Living With the APOE4 Genealzheon2023-01-20T11:31:56-05:00January 20th, 2023|
